Nuvectis Pharma (NVCT) executive compensation, 2026 proxy

Ron Bentsur, Chairman & CEO, was paid $2.6M in 2025, up 124% from $1.2M the year before.

Filed
April 27, 2026
Annual meeting
June 11, 2026
Pay year
2025
Named executives
3
CEO total pay
$2.6M+124% vs prior year
CEO pay in equity
54%$1.4M in awards
CEO 2025 Stock Awards
$1,395,000250,000 shares granted

How Bentsur was paid

$2.6M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary25%Bonus21%Stock awards54%

Named executive officers

ExecutiveTotal
Ron BentsurChairman & CEO$2,588,526
Enrique PoradosuChief Scientific & Business Officer$1,586,241
Shay ShemeshChief Development and Operations Officer$1,586,241

What changed and why

  • $2.6MRon Bentsur received a total compensation of $2,588,526 in fiscal 2025, representing an increase from the prior year total of $1,157,639.
  • Ron Bentsur was granted 250,000 shares of restricted stock in fiscal 2025, compared to zero stock awards in fiscal 2024.
  • Portions of the reported 2025 salaries and bonuses for executive officers remained unpaid as of the filing date.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.